Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV

NCT00863239 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: ribavirin
DRUG: Locteron™ (controlled-release interferon alpha 2b)
DRUG: PEG-Intron™

Sponsor

Biolex Therapeutics, Inc.